AccScience Publishing / GPD / Volume 2 / Issue 2 / DOI: 10.36922/gpd.282
Cite this article
92
Download
2089
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
REVIEW

Basic and clinical insights of Mu (μ)-opioid receptor in cancer

Ruidong Ding1† Yiming Zhao1† Jia Li1† Siyuan Zhao1 Dingyuan Su1 Yue Zhang2 Jia-Yi Wang3 Shuangyu Lv1* Xinying Ji1*
Show Less
1 Institute of Molecular Medicine, Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China
2 Department of Obstetrics and Gynecology, 988 Hospital of PLA, Zhengzhou, Henan 450000, China
3 San-Quan College, Xinxiang Medical University, Xinxiang, Henan 453003, China
Submitted: 1 December 2022 | Accepted: 13 March 2023 | Published: 29 March 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Cancer is a public health problem that is extremely harmful to people’s health. Most cancer patients experience severe pain in the advanced stage, which will seriously affect their prognosis. At present, opioids, such as morphine, have been used as the drug of choice for treating moderate to severe cancer-related pain. Mu (μ)-opioid receptor (MOR) is expressed in many different cancer cells. In this article, we present the relationship between MOR and tumor pathophysiology; summarize the molecular mechanism and effect of MOR on tumor proliferation and progression, tumor angiogenesis, tumor immunity, and cancer therapy; and propose the future research direction of MOR for cancer treatment. MOR could be as a promising prognostic biomarker and immune checkpoint in cancer therapy.

Keywords
Opioids
Mu-opioid receptor
Cancer
Angiogenesis
Immunotherapy
Funding
Program for Innovative Talents of Science and Technology in Henan Province
Natural Science Foundation of Henan Province for Excellent Young Scholars
Medical Science and Technology Program of Henan Province
Program for Young Key Teacher of Henan Province
References
[1]

Sung H, Ferlay J, Siegel RL, et al., 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3): 209–249. https://doi.org/10.3322/caac.21660

[2]

Bray F, Laversanne M, Weiderpass E, et al., 2021, The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 127(6): 3029–30. https://doi.org/10.1002/cncr.33587 

[3]

Xia C, Dong X, Li H, et al., 2022, Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin Med J (Engl), 135(5): 584–590. https://doi.org/10.1097/CM9.0000000000002108 

[4]

Avella Patino DM, Radhakrishnan V, Suvilesh KN, et al., 2022, Epigenetic regulation of cancer immune cells. Semin Cancer Biol, 83: 377–383. https://doi.org/10.1016/j.semcancer.2021.06.022 

[5]

Chen C, Man N, Liu F, et al., 2022, Epigenetic and transcriptional regulation of innate immunity in cancer. Cancer Res, 82(11): 2047–2056. https://doi.org/10.1158/0008-5472.CAN-21-3503

[6]

Berdasco M, Esteller M, 2010, Aberrant epigenetic landscape in cancer: How cellular identity goes awry. Dev Cell, 19(5): 698–711. https://doi.org/10.1016/j.devcel.2010.10.005

[7]

Torry DS, Cooper GM, 1991, Proto-oncogenes in development and cancer. Am J Reprod Immunol, 25(3): 129–132. https://doi.org/10.1111/j.1600-0897.1991.tb01080.x 

[8]

Spandidos DA, Anderson ML, 1989, Oncogenes and onco-suppressor genes: Their involvement in cancer. J Pathol, 157(1): 1–10. https://doi.org/10.1002/path.1711570102

[9]

Sharma S, Kelly TK, Jones PA, 2010, Epigenetics in cancer. Carcinogenesis, 31(1): 27–36. https://doi.org/10.1093/carcin/bgp220 

[10]

Baeriswyl V, Christofori G, 2009, The angiogenic switch in carcinogenesis. Semin Cancer Biol, 19(5): 329–337. https://doi.org/10.1016/j.semcancer.2009.05.003

[11]

Bergers G, Benjamin LE, 2003, Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 3(6): 401–410. https://doi.org/10.1038/nrc1093

[12]

Robert J, 2013, Biology of cancer metastasis. Bull Cancer, 100(4): 333–342. https://doi.org/10.1684/bdc.2013.1724

[13]

Suhail Y, Cain MP, Vanaja K, et al., 2019, Systems biology of cancer metastasis. Cell Syst, 9(2): 109–127. https://doi.org/10.1016/j.cels.2019.07.003

[14]

Fidler IJ, 2003, The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev Cancer, 3(6): 453–458. https://doi.org/10.1038/nrc1098 

[15]

Lambert AW, Pattabiraman DR, Weinberg RA, 2017, Emerging biological principles of metastasis. Cell, 168(4): 670–691. https://doi.org/10.1016/j.cell.2016.11.037 

[16]

Massague J, Obenauf AC, 2016, Metastatic colonization by circulating tumour cells. Nature, 529(7586): 298–306. https://doi.org/10.1038/nature17038

[17]

Li Y, Li F, Jiang F, et al., 2016, A mini-review for cancer immunotherapy: Molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci, 17(7): 1151. https://doi.org/10.3390/ijms17071151 

[18]

Zhang H, Zhou D, Gu J, et al., 2021, Targeting the mu-opioid receptor for cancer treatment. Curr Oncol Rep, 23(10): 111. https://doi.org/10.1007/s11912-021-01107-w

[19]

Ramirez MF, Gorur A, Cata JP, 2021, Opioids and cancer prognosis: A summary of the clinical evidence. Neurosci Lett, 746: 135661. https://doi.org/10.1016/j.neulet.2021.135661 

[20]

Trescot AM, Datta S, Lee M, et al., 2008, Opioid pharmacology. Pain Physician, 11(2 Suppl): S133–S153.

[21]

Spetea M, Schmidhammer H, 2020, Opioids and their receptors: Present and emerging concepts in opioid drug discovery. Molecules, 25(23): 5658. https://doi.org/10.3390/molecules25235658 

[22]

Ballantyne JC, 2006, Opioids for chronic nonterminal pain. South Med J, 99(11): 1245–1255. https://doi.org/10.1097/01.smj.0000223946.19256.17

[23]

Hughes J, Smith TW, Kosterlitz HW, et al., 1975, Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature, 258(5536): 577–580. https://doi.org/10.1038/258577a0

[24]

Rosenblum A, Marsch LA, Joseph H, et al., 2008, Opioids and the treatment of chronic pain: Controversies, current status, and future directions. Exp Clin Psychopharmacol, 16: 405–416. https://doi.org/10.1037/a0013628

[25]

Dickenson AH, 1994, The localization and mechanisms of action of opioids. Eksp Klin Farmakol, 57(6): 3–12. 

[26]

Bovill JG, 1997, Mechanisms of actions of opioids and non-steroidal anti-inflammatory drugs. Eur J Anaesthesiol Suppl, 15: 9–15. https://doi.org/10.1097/00003643-199705001-00003 

[27]

Nelson AD, Camilleri M, 2016, Opioid-induced constipation: Advances and clinical guidance. Ther Adv Chronic Dis, 7(2): 121–134. https://doi.org/10.1177/2040622315627801

[28]

Pattinson KT, 2008, Opioids and the control of respiration. Br J Anaesth, 100(6): 747–758. https://doi.org/10.1093/bja/aen094 

[29]

Mao J, 2002, Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain, 100: 213–217. https://doi.org/10.1016/S0304-3959(02)00422-0 

[30]

DeLeo JA, Tanga FY, Tawfik VL, 2004, Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist, 10(1): 40–52. https://doi.org/10.1177/1073858403259950

[31]

Stein C, Zollner C, 2009, Opioids and sensory nerves. Handb Exp Pharmacol, 194: 495–518. https://doi.org/10.1007/978-3-540-79090-7_14

[32]

Kosten TR, 1990, Neurobiology of abused drugs. Opioids and stimulants. J Nerv Ment Dis, 178(4): 217–227. https://doi.org/10.1097/00005053-199004000-00001

[33]

Colasanti A, Rabiner EA, Lingford-Hughes A, et al., 2011, Opioids and anxiety. J Psychopharmacol, 25: 1415–1433. 

[34]

Waldhoer M, Bartlett SE, Whistler JL, 2004, Opioid receptors. Annu Rev Biochem, 73: 953–990. https://doi.org/10.1146/annurev.biochem.73.011303.073940 

[35]

Zaki PA, Bilsky EJ, Vanderah TW, et al., 1996, Opioid receptor types and subtypes: The delta receptor as a model. Annu Rev Pharmacol Toxicol, 36: 379–401. https://doi.org/10.1146/annurev.pa.36.040196.002115

[36]

Kieffer BL, Evans CJ, 2009, Opioid receptors: From binding sites to visible molecules in vivo. Neuropharmacology, 56 Suppl 1: 205–212. https://doi.org/10.1016/j.neuropharm.2008.07.033 

[37]

Mansour A, Fox CA, Akil H, et al., 1995, Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications. Trends Neurosci, 18(1): 22–29. https://doi.org/10.1016/0166-2236(95)93946-u

[38]

Xia Y, Haddad GG, 1991, Ontogeny and distribution of opioid receptors in the rat brainstem. Brain Res, 549(2): 181–193. https://doi.org/10.1016/0006-8993(91)90457-7 

[39]

Wittert G, Hope P, Pyle D, 1996, Tissue distribution of opioid receptor gene expression in the rat. Biochem Biophys Res Commun, 218(3): 877–881. https://doi.org/10.1006/bbrc.1996.0156

[40]

Peng J, Sarkar S, Chang SL, 2012, Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug Alcohol Depend, 124(3): 223–228. https://doi.org/10.1016/j.drugalcdep.2012.01.013

[41]

Mollereau C, Parmentier M, Mailleux P, et al., 1994, ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett, 341(1): 33–38. https://doi.org/10.1016/0014-5793(94)80235-1 

[42]

Meunier JC, Mollereau C, Toll L, et al., 1995, Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature, 377(6549): 532–535. https://doi.org/10.1038/377532a0 

[43]

Akil H, Watson SJ, Young E, et al., 1984, Endogenous opioids: Biology and function. Annu Rev Neurosci, 7: 223–255. https://doi.org/10.1146/annurev.ne.07.030184.001255 

[44]

Kieffer BL, 1995, Recent advances in molecular recognition and signal transduction of active peptides: Receptors for opioid peptides. Cell Mol Neurobiol, 15(6): 615–635. https://doi.org/10.1007/BF02071128

[45]

Colvin LA, Bull FB, Hales TG, 2019, Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet, 393(10180): 1558–1568. https://doi.org/10.1016/S0140-6736(19)30430-1

[46]

Streicher JM, Bilsky EJ, 2018, Peripherally acting mu-opioid receptor antagonists for the treatment of opioid-related side effects: Mechanism of action and clinical implications. J Pharm Pract, 31(6): 658–669. https://doi.org/10.1177/0897190017732263

[47]

Trang T, Al-Hasani R, Salvemini D, et al., 2015, Pain and poppies: The good, the bad, and the ugly of opioid analgesics. J Neurosci, 35(41): 13879–13888. https://doi.org/10.1523/JNEUROSCI.2711-15.2015

[48]

Eisenstein TK, 2019, The role of opioid receptors in immune system function. Front Immunol, 10: 2904. https://doi.org/10.3389/fimmu.2019.02904 

[49]

Giugliano D, Torella R, Lefèbvre PJ, et al., 1988, Opioid peptides and metabolic regulation. Diabetologia, 31(1): 3–15. https://doi.org/10.1007/BF00279126 

[50]

Meng J, Yu H, Ma J, et al., 2013, Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner. PLoS One, 89(1): e54040. https://doi.org/10.1371/journal.pone.0054040

[51]

Tuerxun H, Cui J, 2019, The dual effect of morphine on tumor development. Clin Transl Oncol, 21(6): 695–701. https://doi.org/10.1007/s12094-018-1974-5

[52]

Gupta K, Chen C, Lutty GA, et al., 2019, Morphine promotes neovascularizing retinopathy in sickle transgeneic mice. Blood Adv, 3(7): 1073–1083. https://doi.org/10.1182/bloodadvances.2018026898

[53]

Lu H, Zhang H, Weng ML, et al., 2021, Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer. J Cell Physiol, 236(6): 4445–4454. https://doi.org/10.1002/jcp.30161

[54]

Zhang H, Sun M, Zhou D, et al., 2020, Increased mu-opioid receptor expression is associated with reduced disease-free and overall survival in laryngeal squamous cell carcinoma. Br J Anaesth, 125(5): 722–729. https://doi.org/10.1016/j.bja.2020.07.051

[55]

Zhang JJ, Song CG, Dai JM, et al., 2021, Inhibition of mu-opioid receptor suppresses proliferation of hepatocellular carcinoma cells via CD147-p53-MAPK cascade signaling pathway. Am J Transl Res, 13(5): 3967–3986. 

[56]

Janku F, Johnson LK, Karp DD, et al., 2016, Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol, 27(11): 2032–2038. https://doi.org/10.1093/annonc/mdw317

[57]

Kieffer BL, 1999, Opioids: First lessons from knockout mice. Trends Pharmacol Sci, 20(1): 19–26. https://doi.org10.1016/s0165-6147(98)01279-6

[58]

Corder G, Castro DC, Bruchas MR, et al., 2018, Endogenous and exogenous opioids in pain. Annu Rev Neurosci, 41: 453–473. https://doi.org/10.1146/annurev-neuro-080317-061522 

[59]

Erbs E, Faget L, Scherrer G, et al., 2015, A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct Funct, 220(2): 677–702. https://doi.org/10.1007/s00429-014-0717-9

[60]

Fields H, 2004, State-dependent opioid control of pain. Nat Rev Neurosci, 5(7): 565–575. https://doi.org/10.1038/nrn1431

[61]

Scherrer G, Imamachi N, Cao YQ, et al., 2009, Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell, 137(6): 1148–1159. https://doi.org/10.1016/j.cell.2009.04.019

[62]

Pasternak GW, Pan YX, 2013, Mu opioids and their receptors: Evolution of a concept. Pharmacol Rev, 65(4): 1257–1317. https://doi.org/10.1124/pr.112.007138 

[63]

Stein C, 2016, Opioid receptors. Annu Rev Med, 67: 433–451. https://doi.org/10.1146/annurev-med-062613-093100 

[64]

Spike RC, Puskár Z, Sakamoto H, et al., 2002, MOR-1- immunoreactive neurons in the dorsal horn of the rat spinal cord: Evidence for nonsynaptic innervation by substance P-containing primary afferents and for selective activation by noxious thermal stimuli. Eur J Neurosci, 15(8): 1306–1316. https://doi.org/10.1046/j.1460-9568.2002.01969.x 

[65]

Wang D, Tawfik VL, Corder G, et al., 2018, Functional divergence of Delta and Mu opioid receptor organization in CNS pain circuits. Neuron, 98(1): 90–108.e5. https://doi.org/10.1016/j.neuron.2018.03.002

[66]

Gardon O, Faget L, Chu Sin Chung P, et al., 2014, Expression of mu opioid receptor in dorsal diencephalic conduction system: New insights for the medial habenula. Neuroscience, 277: 595–609. https://doi.org/10.1016/j.neuroscience.2014.07.053

[67]

Wager TD, Scott DJ, Zubieta JK, 2007, Placebo effects on human mu-opioid activity during pain. Proc Natl Acad Sci U S A, 104(26): 11056–11061. https://doi.org/10.1073/pnas.0702413104

[68]

Zubieta JK, Bueller JA, Jackson LR, et al., 2005, Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci, 25(34): 7754–7562. https://doi.org/10.1523/JNEUROSCI.0439-05.2005

[69]

Cheng S, Guo M, Liu Z, et al., 2019, Morphine promotes the angiogenesis of postoperative recurrent tumors and metastasis of dormant breast cancer cells. Pharmacology, 104(5–6): 276–286. https://doi.org/10.1159/000502107

[70]

Song Z, Huang S, Yu H, et al., 2017, Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC). Eur J Med Chem, 133: 329–339. https://doi.org/10.1016/j.ejmech.2017.03.083

[71]

Ma M, Wang X, Liu N, et al., 2020, Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway. Int Immunopharmacol, 83: 106388. https://doi.org/10.1016/j.intimp.2020.106388

[72]

Cata JP, Uhelski ML, Gorur A, et al., 2002, The μ-opioid receptor in cancer and its role in perineural invasion: A short review and new evidence. Adv Biol (Weinh), 6(9): e2200020. https://doi.org/10.1002/adbi.202200020

[73]

Scopsi L, Balslev E, Brünner N, et al., 1989, Immunoreactive opioid peptides in human breast cancer. Am J Pathol, 134(2): 473–479. 

[74]

Bortsov AV, Millikan RC, Belfer I, et al., 2012, μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology, 116(4): 896–902. https://doi.org/10.1097/ALN.0b013e31824b96a1

[75]

Cao W, Lee H, Wu W, et al., 2020, Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. Nat Commun, 11(1): 3675. https://doi.org/10.1038/s41467-020-17227-z 

[76]

Gao P, Mu M, Chen Y, et al., 2021, Corrigendum to “Yes-associated protein upregulates filopodia formation to promote alveolar epithelial-cell phagocytosis” Immunol. Lett. 225 (2020) 44-49]. Immunol Lett, 239: 113–115. https://doi.org/10.1016/j.imlet.2021.03.005

[77]

Lu Z, Xu J, Xu M, et al., 2018, Truncated μ-opioid receptors with 6 transmembrane domains are essential for opioid analgesia. Anesth Analg, 126(3): 1050–1057. https://doi.org/10.1213/ANE.0000000000002538 

[78]

Zhang H, 2022, Cancer pain management-new therapies. Curr Oncol Rep, 24(2): 223–226. https://doi.org/10.1007/s11912-021-01166-z

[79]

Santoni A, Santoni M, Arcuri E, 2022, Chronic cancer pain: Opioids within tumor microenvironment affect neuroinflammation, tumor and pain evolution. Cancers (Basel), 14(9): 2253. https://doi.org/10.3390/cancers14092253

[80]

Scroope CA, Singleton Z, Hollmann MW, et al., 2021, Opioid receptor-mediated and non-opioid receptor-mediated roles of opioids in tumour growth and metastasis. Front Oncol, 11: 792290. https://doi.org/10.3389/fonc.2021.792290

[81]

Heaney A, Buggy DJ, 2012, Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth, 109 Suppl 1: i17–i28. https://doi.org/10.1093/bja/aes421

[82]

Li Y, Li G, Tao T, et al., 2019, The μ-opioid receptor (MOR) promotes tumor initiation in hepatocellular carcinoma. Cancer Lett, 453: 1–9. https://doi.org/10.1016/j.canlet.2019.03.038 

[83]

Rogers JB, Higa GM, 2022, Spoken and unspoken matters regarding the use of opioids in cancer. J Pain Res, 15: 909–924. https://doi.org/10.2147/JPR.S349107

[84]

Zylla D, Gourley BL, Vang D, et al., 2013, Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer, 119(23): 4103–4110. https://doi.org/10.1002/cncr.28345

[85]

Lennon FE, Mirzapoiazova T, Mambetsariev B, et al., 2012, Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology, 116(4): 857–867. https://doi.org/10.1097/ALN.0b013e31824babe2 

[86]

Liu X, Yang J, Yang C, et al., 2021, Morphine promotes the malignant biological behavior of non-small cell lung cancer cells through the MOR/Src/mTOR pathway. Cancer Cell Int, 21(1): 622. https://doi.org/10.1186/s12935-021-02334-8 

[87]

Lu J, Liu Z, Zhao L, et al., 2013, In vivo and in vitro inhibition of human liver cancer progress by downregulation of the μ-opioid receptor and relevant mechanisms. Oncol Rep, 30(4): 1731–1738. https://doi.org/10.3892/or.2013.2640

[88]

Belltall A, Mazzinari G, Garrido-Cano I, et al., 2022, Opioid receptor expression in colorectal cancer: A nested matched case-control study. Front Oncol, 12: 801714. https://doi.org/10.3389/fonc.2022.801714

[89]

Haque MR, Barlass U, Armstrong A, et al., 2022, Novel role of the Mu-opioid receptor in pancreatic cancer: Potential link between opioid use and cancer progression. Mol Cell Biochem, 477(5): 1339–1345. https://doi.org/10.1007/s11010-022-04377-5 

[90]

Li T, Kang G, Wang T, et al., 2018, Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett, 16(1): 687–702. https://doi.org/10.3892/ol.2018.8733

[91]

Harry JA, Ormiston ML, 2021, Novel pathways for targeting tumor angiogenesis in metastatic breast cancer. Front Oncol, 11: 772305. https://doi.org/10.3389/fonc.2021.772305

[92]

Koodie L, Ramakrishnan S, Roy S, 2010, Morphine suppresses tumor angiogenesis through a HIF-1alpha/ p38MAPK pathway. Am J Pathol, 177(2): 984–997. https://doi.org/10.2353/ajpath.2010.090621 

[93]

Singleton PA, Mirzapoiazova T, Hasina R, et al., 2014, Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth, 113 Suppl 1: i103–i108. https://doi.org/10.1093/bja/aeu165

[94]

Bimonte S, Barbieri A, Rea D, et al., 2015, Morphine promotes tumor angiogenesis and increases breast cancer progression. Biomed Res Int, 2015: 161508. https://doi.org/10.1155/2015/161508

[95]

Murohara T, Asahara T, 2002, Nitric oxide and angiogenesis in cardiovascular disease. Antioxid Redox Signal, 4(5): 825–831. https://doi.org/10.1089/152308602760598981

[96]

Dimmeler S, Zeiher AM, 2000, Endothelial cell apoptosis in angiogenesis and vessel regression. Circ Res, 87(6): 434–439.

[97]

Hsiao PN, Chang MC, Cheng WF, et al., 2009, Morphine induces apoptosis of human endothelial cells through nitric oxide and reactive oxygen species pathways. Toxicology, 256(1–2): 83–91. https://doi.org/10.1016/j.tox.2008.11.015

[98]

Ziche M, Morbidelli L, 2000, Nitric oxide and angiogenesis. J Neurooncol, 50(1–2): 139–148. https://doi.org/10.1023/a:1006431309841 

[99]

Kenny PA, Lee GY, Bissell MJ, Targeting the tumor microenvironment. Front Biosci, 12: 3468–3474. https://doi.org/10.2741/2327

[100]

Sung SY, Hsieh CL, Wu D, et al., 2007, Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer, 31(2): 36–100. https://doi.org10.1016/j.currproblcancer.2006.12.002

[101]

Fang H, Declerck YA, 2013, Targeting the tumor microenvironment: From understanding pathways to effective clinical trials. Cancer Res, 73(16): 4965–4977. https://doi.org/10.1158/0008-5472.CAN-13-0661

[102]

Liang X, Liu R, Chen C, et al., 2016, Opioid system modulates the immune function: A review. Transl Perioper Pain Med, 1(1): 5–13.

[103]

Koodie L, Yuan H, Pumper JA, et al., 2014, Morphine inhibits migration of tumor-infiltrating leukocytes and suppresses angiogenesis associated with tumor growth in mice. Am J Pathol, 184(4): 1073–1084. https://doi.org/10.1016/j.ajpath.2013.12.019

[104]

Jiang Y, Li T, Qian Y, et al., 2022, Morphine in combination with ketamine improves cervical cancer pain and suppresses immune function via the JAK3/STAT5 pathway. Pain Res Manag, 2022: 9364365. https://doi.org/10.1155/2022/9364365

[105]

Zielińska M, Szymaszkiewicz A, Jacenik D, et al., 2020, Cyclic derivative of morphiceptin Dmt-cyclo-(D-Lys-Phe- D-Pro-Asp)-NH2(P-317), a mixed agonist of MOP and KOP opioid receptors, exerts anti-inflammatory and anti-tumor activity in colitis and colitis-associated colorectal cancer in mice. Eur J Pharmacol, 885: 173463. https://doi.org/10.1016/j.ejphar.2020.173463

[106]

Boehncke S, Hardt K, Schadendorf D, et al., 2011, Endogenous μ-opioid peptides modulate immune response towards malignant melanoma. Exp Dermatol, 20(1): 24–28. https://doi.org/10.1111/j.1600-0625.2010.01158.x 

[107]

Coluzzi F, Rullo L, Scerpa MS, et al., 2022, Current and future therapeutic options in pain management: Multi-mechanistic opioids involving both MOR and NOP receptor activation. CNS Drugs, 36(6): 617–632. https://doi.org/10.1007/s40263-022-00924-2

[108]

Gorur A, Patiño M, Shi T, et al., 2021, Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor. J Cell Physiol, 236(11): 7698–7710. https://doi.org/10.1002/jcp.30421

[109]

Singleton PA, Moss J, 2010, Effect of perioperative opioids on cancer recurrence: A hypothesis. Future Oncol, 6(8): 1237–1242. https://doi.org/10.2217/fon.10.99

[110]

da Silva JL, Dos Santos AL, Nunes NC, de Moraes Lino da Silva F, et al., 2019, Cancer immunotherapy: The art of targeting the tumor immune microenvironment. Cancer Chemother Pharmacol, 84(4): 227–240. https://doi.org/10.1007/s00280-019-03894-3 

[111]

Esfahani K, Roudaia L, Buhlaiga N, et al., 2020, A review of cancer immunotherapy: From the past, to the present, to the future. Curr Oncol, 27: S87–S97. https://doi.org/10.3747/co.27.5223 

[112]

Emens LA, 2018, Breast cancer immunotherapy: Facts and hopes. Clin Cancer Res, 24(3): 511–520. https://doi.org/10.1158/1078-0432.CCR-16-3001

[113]

Chen G, Kim YH, Li H, et al., 2017, PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. Nat Neurosci, 20(7): 917–926. https://doi.org/10.1038/nn.4571

[114]

McLaughlin PJ, Verderame MF, Hankins JL, et al., 2007, Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. Int J Mol Med, 19(3): 421–428.

[115]

Zagon IS, McLaughlin PJ, 2014, Opioid growth factor and the treatment of human pancreatic cancer: A review. World J Gastroenterol, 20(9): 2218–2223. https://doi.org/10.3748/wjg.v20.i9.2218 

[116]

Kim JY, Ahn HJ, Kim JK, et al., 2016, Morphine suppresses lung cancer cell proliferation through the interaction with opioid growth factor receptor: An in vitro and human lung tissue study. Anesth Analg, 123(3): 1429–1436.

[117]

Ma Y, Ren Z, Ma S, et al., 2017, Morphine enhances renal cell carcinoma aggressiveness through promotes survivin level. Ren Fail, 39(1): 258–64.

[118]

Belltall A, Zúñiga-Trejos S, Garrido-Cano I, et al., 2022, Solid tumor opioid receptor expression and oncologic outcomes: Analysis of the cancer genome atlas and genotype tissue expression project. Front Oncol, 12: 801411. https://doi.org/10.3389/fonc.2022.801411 

[119]

Zhang H, Qu M, Gorur A, et al., 2021, Association of Mu-opioid receptor(MOR) expression and opioids requirement with survival in patients with stage I-III pancreatic ductal adenocarcinoma. Front Oncol, 11: 686877. https://doi.org/10.3389/fonc.2021.686877 

[120]

Díaz-Cambronero O, Mazzinari G, Giner F, et al., 2020, Mu opioid receptor 1 (MOR-1) expression in colorectal cancer and oncological long-term outcomes: A five-year retrospective longitudinal cohort study. Cancers (Basel), 12(1): 134. https://doi.org/10.3390/cancers12010134

[121]

Wang H, Luo J, Chen X, et al., 2022, Clinical observation of the effects of oral opioid on inflammatory cytokines and gut microbiota in patients with moderate to severe cancer pain: A retrospective cohort study. Pain Ther, 11(2): 667–681. https://doi.org/10.1007/s40122-022-00386-w

[122]

Edwards KA, Havelin JJ, Mcintosh MI, et al., 2018, A kappa opioid receptor agonist blocks bone cancer pain without altering bone loss, tumor size, or cancer cell proliferation in a mouse model of cancer-induced bone pain. J Pain, 19(6): 612–625. https://doi.org/10.1016/j.jpain.2018.01.002

[123]

Huang HM, He XH, Huang XY, et al., 2022, Down-regulation of kappa opioid receptor promotes ESCC proliferation, invasion and metastasis via the PDK1-AKT signaling pathway. Cell Commun Signal, 20(1): 35. https://doi.org/10.1186/s12964-022-00833-3

[124]

Zhang YF, Xu QX, Liao LD, et al., 2013, κ-Opioid receptor in the nucleus is a novel prognostic factor of esophageal squamous cell carcinoma. Hum Pathol, 44(9): 1756–1765. https://doi.org/10.1016/j.humpath.2012.11.025

[125]

Xie N, Matigian N, Vithanage T, et al., 2018, Effect of perioperative opioids on cancer-relevant circulating parameters: Mu opioid receptor and toll-like receptor 4 activation potential, and proteolytic profile. Clin Cancer Res, 24(10): 2319–2327. https://doi.org/10.1158/1078-0432.CCR-18-0172

[126]

Fu J, Xu M, Xu L, et al., 2021, Sulforaphane alleviates hyperalgesia and enhances analgesic potency of morphine in rats with cancer-induced bone pain. Eur J Pharmacol, 909: 174412. https://doi.org/10.1016/j.ejphar.2021.174412

[127]

Maher DP, Wong W, White PF, et al., 2014, Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: A retrospective analysis. Br J Anaesth, 113 Suppl 1: i88–i94. https://doi.org/10.1093/bja/aeu192

[128]

Szczepaniak A, Fichna J, Zielińska M, 2022, Opioids in cancer development, progression and metastasis: Focus on colorectal cancer. Curr Treat Options Oncol, 21(1): 6. https://doi.org/10.1007/s11864-019-0699-1

[129]

Cadet P, Rasmussen M, Zhu W, et al., 2004, Endogenous morphinergic signaling and tumor growth. Front Biosci, 9: 3176–3186. https://doi.org/10.2741/1471

[130]

Tan M, Wang H, Gao C, et al., Agonists specific for kappa-opioid receptor induces apoptosis of HCC cells through enhanced endoplasmic reticulum stress. Front Oncol, 12: 844214. https://doi.org/10.3389/fonc.2022.844214 

[131]

Lin ZZ, Bo N, Fan YC, et al., 2022, Xanthomicrol suppresses human hepatocellular carcinoma cells migration and invasion ability via Μu-opioid receptor. J Pharm Pharmacol, 74(1): 139–146. https://doi.org/10.1093/jpp/rgab104

Conflict of interest
The authors declare no conflict of interest.
Share
Back to top
Gene & Protein in Disease, Electronic ISSN: 2811-003X Published by AccScience Publishing